Skip to nav Skip to content
James  Saller

James Saller, MD

Specialty: Pathology

Program: Pathology

Language(s): English

  • Overview

    Dr. Saller received his MD degree from the American University of Antigua College of Medicine and completed a Pathology Residency at Summa Health System/Northeast Ohio Medical University in Akron, Ohio. From 2015-2020, Dr. Saller completed the following fellowships at Moffitt Cancer Center: Oncologic Molecular Pathology, Personalized Cancer Medicine, Gastrointestinal Oncologic Surgical Pathology, and most recently, a Thoracic Molecular Pathology research fellowship. Dr. Saller’s clinical interests are in molecular testing. His research interests are focused on determining genomic, transcriptomic and proteomic biomarkers with the potential to provide meaningful prognostic information and insight about responsiveness to treatment.

    Education & Training


    • Moffitt Cancer Center - Thoracic Molecular Pathology
    • Moffitt Cancer Center - Gastrointestinal Surgical Pathology
    • Moffitt Cancer Center - Personalized Cancer Medicine
    • Moffitt Cancer Center - Oncologic Molecular Pathology


    • Summa Health System/Northeast Ohio Medical University - Pathology

    Medical School:

    • American University of Antigua College of Medicine - MD
    • University of South Florida Morsani College of Medicine
  • Publications

    • Saeed-Vafa D, Chatzopoulos K, Hernandez-Prera J, Cano P, Saller JJ, Hallanger Johnson JE, McIver B, Boyle TA. RET splice site variants in medullary thyroid carcinoma. Front Genet. 2024 Mar.15:1377158. Pubmedid: 38566816. Pmcid: PMC10985236.
    • Furlan KC, Saeed-Vafa D, Mathew TM, Saller JJ, Tabbara SO, Boyle TA, Wenig BM, Hernandez-Prera JC. Utility of UV Signature Mutations in the Diagnostic Assessment of Metastatic Head and Neck Carcinomas of Unknown Primary. Head Neck Pathol. 2024 Feb.18(1):11. Pubmedid: 38393464. Pmcid: PMC10891032.
    • Nasir A, Ahmed MK, Saller JJ, Henderson-Jackson EB, Malafa MP, Yeatman TJ, Coppola D. p21 Protein Outperforms Clinico-pathological Criteria in Predicting Liver Metastases in Pancreatic Endocrine Tumors. Cancer Genomics Proteomics. 2023 Nov.20(6):522-530. Pubmedid: 37889062. Pmcid: PMC10614061.
    • Saller J, White D, Hough B, Yoder S, Whiting J, Chen DT, Magliocco A, Coppola D. An miRNA Signature Predicts Grading of Pancreatic Neuroendocrine Neoplasms. Cancer Genomics Proteomics. 2023 Mar.20(2):154-164. Pubmedid: 36870693. Pmcid: PMC9989673.
    • Lockhart JH, Ackerman HD, Lee K, Abdalah M, Davis AJ, Hackel N, Boyle TA, Saller J, Keske A, Hänggi K, Ruffell B, Stringfield O, Cress WD, Tan AC, Flores ER. Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI). NPJ Precis Oncol. 2023 Jul.7(1):68. Pubmedid: 37464050. Pmcid: PMC10354042.
    • Saller JJ, Boyle TA. Molecular Pathology of Lung Cancer. Cold Spring Harb Perspect Med. 2022 Mar.12(3). Pubmedid: 34751163. Pmcid: PMC8886739.
    • Saller JJ, Haider M, Al-Diffalha S, Coppola D. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin. Anticancer Res. 2022 Mar.42(3):1381-1396. Pubmedid: 35220231.
    • Saller JJ, Mora LB, Nasir A, Mayer Z, Shahid M, Coppola D. Expression of DNA Mismatch Repair Proteins, PD1 and PDL1 in Barrett's Neoplasia. Cancer Genomics Proteomics. 2022 Mar.19(2):145-150. Pubmedid: 35181584. Pmcid: PMC8865038.
    • Saller J, Jiang K, Xiong Y, Yoder SJ, Neill K, Pimiento JM, Pena L, Corbett FS, Magliocco A, Coppola D. A microRNA Signature Identifies Patients at Risk of Barrett Esophagus Progression to Dysplasia and Cancer. Digest Dis Sci. 2022 Feb.67(2):516-523. Pubmedid: 33713247. Pmcid: PMC9768694.
    • Majumder A, Hosseinian S, Stroud M, Adhikari E, Saller JJ, Smith MA, Zhang G, Agarwal S, Creixell M, Meyer BS, Kinose F, Bowers K, Fang B, Stewart PA, Welsh EA, Boyle TA, Meyer AS, Koomen JM, Haura EB. Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration. Mol Cancer Res. 2022 Apr.20(4):542-555. Pubmedid: 35022314. Pmcid: PMC8983558.
    • Saller J, Hough B, Coppola D. Pancreatic-type Mixed Acinar-neuroendocrine Carcinoma of the Stomach: A Case Report and Literature Review. Cancer Diagn Progn. 2021 Jul.1(4):285-288. Pubmedid: 35403148. Pmcid: PMC8988951.
    • Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, Lannon A, MacMillan G, Saller J, Grass GD, Rosenberg S, Gray J, Haura E, Creelan B, Tanvetyanon T, Saltos A, Shafique M, Boyle TA, Schell MJ, Conejo-Garcia JR, Antonia SJ. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 Feb.109(2):425-435. Pubmedid: 33002543. Pmcid: PMC8465780.
    • Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021 Aug.27(8):1410-1418. Pubmedid: 34385708. Pmcid: PMC8509078.
    • Tunali I, Tan Y, Gray JE, Katsoulakis E, Eschrich SA, Saller J, Aerts HJWL, Boyle T, Qi J, Guvenis A, Gillies RJ, Schabath MB. Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer. JNCI Cancer Spectr. 2021 Aug.5(4). Pubmedid: 34409252. Pmcid: PMC8363765.
    • Stewart PA, Welsh EA, Fang B, Izumi V, Mesa T, Zhang C, Yoder S, Zhang G, Cen L, Pettersson F, Zhang Y, Chen Z, Cheng CH, Thapa R, Thompson Z, Avedon M, Wloch M, Fournier M, Fellows KM, Francis JM, Saller JJ, Boyle TA, Chen YA, Haura EB, Teer JK, Eschrich SA, Koomen JM. Managing a Large-Scale Multiomics Project: A Team Science Case Study in Proteogenomics. Methods Mol Biol. 2020 Sep.2194:187-221. Pubmedid: 32926368. Pmcid: PMC7771375.
    • Boyle TA, Khalil FK, Mino-Kenudson M, Sica GL, Moreira AL, Sholl LM, Knight MZ, Zhang L, Saller J, Varella-Garcia M, Berry LD, Chen H, Ellison KE, Rivard CJ, Kugler K, Wistuba II, Fujimoto J, Kwiatkowski DJ, Bunn PA, Kris MG, Haura EB, Hirsch FR. Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. Appl Immunohistochem Mol Morphol. 2020 Oct.28(9):669-677. Pubmedid: 31876606. Pmcid: PMC7242128.
    • Saller J, Qin D, Felder S, Coppola D. Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment. Clin Colorectal Cancer. 2020 Jun.19(2):123-131. Pubmedid: 32171644.
    • Kang YP, Falzone A, Liu M, González-Sánchez P, Choi BH, Coloff JL, Saller JJ, Karreth FA, DeNicola GM. PHGDH supports liver ceramide synthesis and sustains lipid homeostasis. Cancer Metab. 2020 Jun.8:6. Pubmedid: 32549981. Pmcid: PMC7294658.
    • Saller J, Al Diffalha S, Neill K, Bhaskar RA, Oliveri C, Boulware D, Levine H, Kalvaria I, Corbett FS, Khazanchi A, Klapman J, Coppola D. CDX-2 Expression in Esophageal Biopsies Without Goblet Cell Intestinal Metaplasia May Be Predictive of Barrett's Esophagus. Digest Dis Sci. 2020 Jul.65(7):1992-1998. Pubmedid: 31691172. Pmcid: PMC7771382.
    • Boyle TA, Quinn GP, Schabath MB, Muñoz-Antonia T, Saller JJ, Duarte LF, Hair LS, Teer JK, Chiang DY, Leary R, Wong CC, Savchenko A, Singh AP, Charette L, Mendell K, Gorgun G, Antonia SJ, Chiappori AA, Creelan BC, Gray JE, Haura EB. A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses. Cancer Med. 2020 Jan.9(1):225-237. Pubmedid: 31747139. Pmcid: PMC6943158.
    • Saller J, Seydafkan S, Shahid M, Gadara M, Cives M, Eschrich SA, Boulware D, Strosberg JR, Aejaz N, Coppola D. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors. Cancer Genomics Proteomics. 2019 Sep.16(5):309-318. Pubmedid: 31467225. Pmcid: PMC6727072.
    • Gray JE, Saltos AN, Tanvetyanon T, Haura EB, Creelan BC, Antonia SJ, Shafique M, Zheng H, Dai W, Saller JJ, Chen Z, Tchekmedyian N, Goas K, Thapa R, Boyle TA, Chen DT, Beg AA. Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Nov.25(22):6623-6632. Pubmedid: 31409616. Pmcid: PMC7234799.
    • Shahid M, George TB, Saller J, Haija M, Sayegh Z, Boulware D, Strosberg J, Chakrabarti R, Coppola D. FGD4 (Frabin) Overexpression in Pancreatic Neuroendocrine Neoplasms. Pancreas. 2019 Nov.48(10):1307-1311. Pubmedid: 31688594. Pmcid: PMC7771383.
    • Shahid M, Wang D, Saller J, Ryzhova E, Qin D, Magliocco A, Coppola D. STK11 p.G270W: A Novel Mutation Detected in a Case of MSI High Mixed Medullary-Mucinous Carcinoma of the Transverse Colon. Cancer Genomics Proteomics. 2019 Jul.16(4):267-272. Pubmedid: 31243107. Pmcid: PMC6609257.
    • Stewart PA, Welsh EA, Slebos RJC, Fang B, Izumi V, Chambers M, Zhang G, Cen L, Pettersson F, Zhang Y, Chen Z, Cheng CH, Thapa R, Thompson Z, Fellows KM, Francis JM, Saller JJ, Mesa T, Zhang C, Yoder S, DeNicola GM, Beg AA, Boyle TA, Teer JK, Ann Chen Y, Koomen JM, Eschrich SA, Haura EB. Proteogenomic landscape of squamous cell lung cancer. Nat Commun. 2019 Aug.10(1):3578. Pubmedid: 31395880. Pmcid: PMC6687710.
    • Neill KG, Saller J, Al Diffalha S, Centeno BA, Malafa MP, Coppola D. EGFR L861Q Mutation in a Metastatic Solid-pseudopapillary Neoplasm of the Pancreas. Cancer Genomics Proteomics. 2018 Jun.15(3):201-205. Pubmedid: 29695402. Pmcid: PMC5971012.
    • Saller J, Walko CM, Millis SZ, Henderson-Jackson E, Makanji R, Brohl AS. Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study. J Natl Compr Canc Ne. 2018 Jul.16(7):797-800. Pubmedid: 30006421.
    • Hicks JK, Saller J, Wang E, Boyle T, Gray JE. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results. Lung Cancer. 2017 Sep.111:135-138. Pubmedid: 28838384.
    • Knepper TC, Saller J, Walko CM. Novel and Expanded Oncology Drug Approvals of 2016-PART 1: New Options in Solid Tumor Management. Oncology (Williston Park). 2017 Feb.31(2):110-121. Pubmedid: 28205191.
  • Patient Comments

    Overall Satisfaction


    0 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey



    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor